These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36135828)

  • 1. The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study.
    Ozeki Y; Masaki T; Kamata A; Miyamoto S; Yoshida Y; Okamoto M; Gotoh K; Shibata H
    Medicines (Basel); 2022 Sep; 9(9):. PubMed ID: 36135828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes.
    Uchiyama S; Sada Y; Mihara S; Sasaki Y; Sone M; Tanaka Y
    J Clin Med Res; 2023 Jul; 15(7):377-383. PubMed ID: 37575352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults.
    Xiang J; Ding XY; Zhang W; Zhang J; Zhang YS; Li ZM; Xia N; Liang YZ
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9908-9915. PubMed ID: 37916360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients.
    Masaki T; Ozeki Y; Yoshida Y; Okamoto M; Miyamoto S; Gotoh K; Shibata H
    Metabolites; 2022 Feb; 12(2):. PubMed ID: 35208221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.
    Nunn E; Jaiswal N; Gavin M; Uehara K; Stefkovich M; Drareni K; Calhoun R; Lee M; Holman CD; Baur JA; Seale P; Titchenell PM
    Mol Metab; 2024 Feb; 80():101880. PubMed ID: 38218536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
    Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
    Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism.
    Ren Q; Chen S; Chen X; Niu S; Yue L; Pan X; Li Z; Chen X
    Drug Des Devel Ther; 2022; 16():3723-3735. PubMed ID: 36304787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study.
    Volpe S; Lisco G; Racaniello D; Fanelli M; Colaianni V; Vozza A; Triggiani V; Sabbà C; Tortorella C; De Pergola G; Piazzolla G
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.
    Okamoto A; Yokokawa H; Nagamine T; Fukuda H; Hisaoka T; Naito T
    J Diabetes Metab Disord; 2021 Dec; 20(2):2121-2128. PubMed ID: 34900848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics.
    Inokuchi T; Fukumoto Y; Lee G; Yokomizo Y; Tanaka K; Chosa M; Doi M; Tamaki N; Goto S; Ichikawa K; Kobayashi K
    J Diabetes Investig; 2024 Sep; 15(9):1202-1210. PubMed ID: 38700282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
    Di Loreto C; Minarelli V; Nasini G; Norgiolini R; Del Sindaco P
    Diabetes Ther; 2022 Mar; 13(3):551-567. PubMed ID: 35230650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.
    Jensterle M; Ferjan S; Vovk A; Battelino T; Rizzo M; Janež A
    Diabetes Res Clin Pract; 2021 Aug; 178():108935. PubMed ID: 34217774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Improvement in Weight, Body Composition, and Glucose Variability With Semaglutide in Type 1 Diabetes.
    Gad H; Malik RA
    Cureus; 2024 Jun; 16(6):e61577. PubMed ID: 38962634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
    Nomoto H; Oba-Yamamoto C; Takahashi Y; Takeuchi J; Nagai S; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Kameda H; Cho KY; Nakamura A; Atsumi T; Miyoshi H
    Diabetes Ther; 2021 Mar; 12(3):955-964. PubMed ID: 33491111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
    Paquot N
    Rev Med Liege; 2021 Dec; 76(12):896-903. PubMed ID: 34881835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.